February 04, 2013 at 09:04 AM EST
UPDATE: BMO Capital Markets Reiterates Outperform Rating, Lowers PT on Merck & Co.
In a report published Monday, BMO Capital Markets reiterated its Outperform rating on Merck & Co. (NYSE: MRK ), but slightly lowered its price target from $50.00 to $49.00. BMO Capital Markets noted, “We recommend investors buy MRK shares on weakness. Although the upcoming interim analysis of the IMPROVE-IT trial
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here